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DISCUSSION
Dr Patrick J. Lamparello (New York, NY). NYU is a center
with a large experience in carotid surgery. We have been very inter-
ested in the topic presented today, namely follow-up with duplex
scanning of carotid artery stenosis contralateral to carotid artery end-
arterectomy. The paper presented today yields practical information
and advice on how to follow patients after carotid endarterectomy.
We have long been concerned about the frequency of follow-up for
our patients after carotid surgery. Should patients have follow-up
duplex scans at yearly intervals or can the time between scanning be
increased for patients with mild or moderate stenosis opposite carotid
artery endarterectomy. The data presented today help answer some of
these questions. We are all concerned about the same goal, namely to
prevent our patients from having strokes.
We’re also indebted to Dr AbuRahma for this large series of
patients with excellent data. I have two questions for Dr Abu-
Rahma. May I first say that I enjoyed reading your excellent paper.
I am somewhat concerned about the incidence of late neurologic
events of 6.7%. This seems higher than what it ought to be in a
group of patients who are followed closely and probably have had
other risk factor reduction for stroke such as cessation of smoking,
maintenance of blood pressure control, and anti-platelet medica-
tion. Can you shed any light on this higher incidence of neurologic
events than what we would expect?
My second question relates to the risk factors for progression
of carotid artery stenosis and neurologic events. In your paper you
note that female sex, hypercholesterolemia, and hypertension were
statistically significant for progression of carotid artery stenosis. I
would ask if these risk factors and others that you looked at would
stand the test of a multivariate analysis.
Dr Ali F. AbuRahma. In regard to the late neurologic events,
I agree with you, and the way you define it depends on the clinician
looking at the data. A surgeon would probably consider it relatively
high, but a neurologist may consider it relatively low. Can I justify
doing all of the follow-up to prevent an 11% neurologic event,
particularly the stroke portion of it? My answer is, perhaps, yes. Keep
in mind that all of our patients may not have adhered to our recom-
mendations regarding controlling risk factors, ie, abstinence from
smoking or hypertension. In regard to risk factors, the only risk factors
that we felt were associated with a significant increase of progression in
our study were hypertension and hypercholesterolemia.
Dr Peter J. Pappas (Newark, NY). I’d like to thank you for
bringing this data to our attention. Sitting and listening to your
presentation, I was trying to decide whether the cup was half full or
half empty. You indicated that the majority of stenoses progressed,
but you neglected to indicate the final degree of stenosis. In other
words, a patient who has a 50% stenosis progresses to a 50%
stenosis and remains symptom-free is not clinically relevant. Do
you treat that patient?
I’m assuming that the majority of these patients had asymp-
tomatic disease. And your 10.9% stroke rate essentially confirmed
the ACAS data of the medical arm. So I’m not quite sure what to
do with this information. About half of our patients will progress in
the worst-case scenario. They may progress to a stenosis that I’m
not going to do anything about, and I don’t know if that justifies
performing serial duplex exams on them.
Dr AbuRahma. That’s a good question. Again, back to half
full/half empty, that’s again whether you are an internal medicine
physician or a surgeon. If you’re looking at people on whom to
operate at 80% and above, then I think half full. If you’re looking
at people on whom you’re not going to operate unless they have
symptomatic lesion, that’s probably half empty. So what I’m trying
to tell you is, I don’t blame you, because you don’t have the paper
in front of you, but in our paper we actually not only indicate how
many of these progressed, but if they progressed, that they pro-
gressed to 50%, they progressed to 80%. However, the progression
in our series was, in my judgment, associated with relatively infre-
quent neurologic events, if you are looking at stroke victims only
and not transient ischemic attacks.
Dr Pappas. If I can just follow up with one other question:
I’m really intrigued by this paper because of the previous article
that you published in which you looked at plaque morphology. In
the subset of patients who progressed, did you do any of your
plaque morphology analyses on those patients, and do you think
that plaque morphology is more important than progression?
Dr AbuRahma. That’s an excellent question. In regard to
which patients progressed and to what degree, these data are
available in the paper: whether 50% progressed to 50% and so
forth. It’s true that most of the patients who progressed were
symptom-free, with roughly 11% associated with neurologic events
and around 6% associated with ipsilateral strokes. In regard to
managing these patients, if the patients were50 percent and had
symptoms, they generally underwent surgery. However, in symp-
tom-free patients, surgery was considered if progression reached
80% and above, which is similar to what most authorities would do,
particularly in good-risk patients. Keep in mind, all of the patients
who were enrolled in this prospective trial had asymptomatic
stenoses that were not initially operated on.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 6 AbuRahma et al 1161
